Literature DB >> 7911276

Splanchnic and systemic absorption of intraperitoneal insulin using a new double-tracer method.

J Radziuk1, S Pye, D E Seigler, J S Skyler, R Offord, G Davies.   

Abstract

The absorption of a bolus of intraperitoneal insulin into the splanchnic and peripheral circulations was separately assessed in dogs using an infusion of two insulin tracers (A1-[3H]insulin and B1-[3H]insulin). One tracer was infused into the superior mesenteric artery and the second into the jugular vein. Serial samples were taken before and after an injection of insulin (1 U/kg ip). Sampling was from the portal vein and the inferior vena cava. By using the principle of equivalent entry of tracer and unlabeled material, we developed two simultaneous equations for the rate of splanchnic and peripheral insulin absorption at each time point. These were solved to yield the two rates. Mean concentrations in the portal vein were approximately 25% higher than in the inferior vena cava, reflecting the splanchnic absorption. This rate accounted for almost half (51 +/- 9%) of the insulin absorbed. The remainder of the absorption was peripheral. The total recovery of intraperitoneal insulin, absorbed by either route, was 88 +/- 11%. Portal absorption peaked earlier than peripheral. Absorption by both routes was 90% complete within approximately 2 h (131 +/- 16 min). In summary, therefore, intraperitoneal insulin is rapidly and almost completely absorbed, with absorption split between the splanchnic and peripheral routes of entry.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911276     DOI: 10.1152/ajpendo.1994.266.5.E750

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

2.  A New Optimized Percutaneous Access System for CIPII.

Authors:  Rosa Garcia-Verdugo; Michael Erbach; Oliver Schnell
Journal:  J Diabetes Sci Technol       Date:  2017-03-01

3.  Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes.

Authors:  Rayhan A Lal; Laya Ekhlaspour; Korey Hood; Bruce Buckingham
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

4.  Quantification of β-cell insulin secretory function using a graded glucose infusion with C-peptide deconvolution in dysmetabolic, and diabetic cynomolgus monkeys.

Authors:  Xiaoli Wang; Barbara C Hansen; Da Shi; Yupeng Fang; Fenglai Du; Bingdi Wang; Yaxiong Michael Chen; Francine M Gregoire; Yi-Xin Jim Wang
Journal:  Diabetol Metab Syndr       Date:  2013-07-25       Impact factor: 3.320

5.  Favourable serum calcification propensity with intraperitoneal as compared with subcutaneous insulin administration in type 1 diabetes.

Authors:  Peter R van Dijk; Femke Waanders; Andreas Pasch; Susan J J Logtenberg; Titia Vriesendorp; Klaas H Groenier; Jan-Luuk Hillebrands; Nanno Kleefstra; Rijk O B Gans; Harry van Goor; Henk J G Bilo
Journal:  Ther Adv Endocrinol Metab       Date:  2020-03-03       Impact factor: 3.565

6.  The artificial pancreas.

Authors:  Jerry Radziuk
Journal:  Diabetes       Date:  2012-09       Impact factor: 9.461

7.  Effects of intraperitoneal insulin versus subcutaneous insulin administration on sex hormone-binding globulin concentrations in patients with type 1 diabetes mellitus.

Authors:  M Boering; P R van Dijk; S J J Logtenberg; K H Groenier; B H R Wolffenbuttel; R O B Gans; N Kleefstra; H J G Bilo
Journal:  Endocr Connect       Date:  2016-05       Impact factor: 3.335

8.  Intraperitoneal and subcutaneous glucagon delivery in anaesthetized pigs: effects on circulating glucagon and glucose levels.

Authors:  Marte Kierulf Åm; Ilze Dirnena-Fusini; Anders Lyngvi Fougner; Sven Magnus Carlsen; Sverre Christian Christiansen
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.